Pyrexar Medical In The News

San Francisco, Calif. — March 16, 2005 — Frost & Sullivan will present its 2005 Cancer Therapy Solutions Technology Innovation Award to BSD Medical Corporation at tonight’s second annual Excellence in Medical Devices & Healthcare Awards Banquet.

BSD Medical is recognized for its development of the innovative BSD-2000 Hyperthermia System, which is a cutting-edge cancer therapy that destroys cancer cells effectively and imparts an additive effect when used in combination with existing therapies.

BSD Medical’s hyperthermia systems increase the temperature of cancerous tumors up to 104 to 113 degrees F, selectively killing cancer cells that are particularly vulnerable to destruction by heat. Conventional surface treatment methods do not heat tumors that exist more than a few centimeters below the surface of the skin. Thus, they leave deep tumors unaffected.

"The BSD-2000 technology overcomes such limitations by heating the tumor from inside out, employing a series of patented annular phased-array of radiofrequency antennae that produce energy waves, which pass harmlessly through the body," says Frost & Sullivan research analyst A.N. Aditya. "BSD's technology focuses the energy waves on targeting the site of the tumor specifically."

When the energy waves intersect, enough energy is created to heat the tumor to therapeutic temperatures. Intervening tissues remain unaffected by these waves. Random clinical trials conducted on a variety of cancerous tissues have highlighted the advantage of adding hyperthermia therapy to a standard radiotherapy/chemotherapy regimen. Hyperthermia can even reduce the size of some tumors, making them easier to remove through surgery.

Hyperthermia has proven its efficiency over standard treatments, and the ongoing protocols have marked regional hyperthermia as an essential modality in the prevention and treatment of recurrent and advanced cancer. BSD Medical is the first company to obtain premarket approval from the Food and Drug Administration (FDA) for such a hyperthermia-based cancer therapy system.

"Substantial effort has been put into the development of the BSD-2000 by researchers hailing from top American and European research institutions," observes Aditya. "Additionally, with the support of institutions such as the U.S. National Cancer Institute, further product line enhancements in the form of BSD-2000/3D and BSD-2000/3D/MR have been made."

As a result of all these concentrated R&D activities, BSD-2000/3D can offer three-dimensional steering of deep focused energy, providing greater heating precision to the tumor site. Meanwhile, the BSD-2000/3D/MR includes magnetic resonance imaging (MRI) as an interface with the BSD-2000/3D.

Frost & Sullivan presents its Technology Innovation of the Year Award each year to the company that has excelled in its market by outclassing the competition in all stages of the technology lifecycle – incubation, adoption, take-up, and maturity. By innovating leading-edge concepts, the company has pioneered client applications for the market. The superior technological sophistication has set the company on a growth trajectory in the market.

Held in San Francisco, Frost & Sullivan’s 2005 Excellence in Medical Devices & Healthcare Awards Banquet honors world-class companies for outstanding performance and achievements

in the medical devices industry. An annual event, the banquet recognizes the quality and merit of distinguished individuals and companies.

About BSD Medical Corporation

BSD Medical Corporation is the leading developer of systems used to treat cancer at hyperthermic temperatures using focused electromagnetic energy. The BSD-2000 is used to superheat and kill cancer cells, as well as to boost the effectiveness of radiation and chemotherapy in the effort to improve local control of cancer and increase long-term survival. The BSD-2000 employs a revolutionary annular phased array of radiofrequency (RF) antennae placed around the patient to focus RF energy on tumors, including those located deep in the body. For more information about BSD Medical Corp. and its systems, visit

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, founded in 1961, partners with clients to create value through innovative growth strategies. The foundation of this partnership approach is our Growth Partnership Services platform, whereby we provide industry research, marketing strategies, consulting, and training to our clients to help grow their business. A key benefit that Frost & Sullivan brings to its clients is a global perspective on a broad range of industries, markets, technologies, econometrics, and demographics. With a client list that includes Global 1000 companies, emerging companies, as well as the investment community, Frost & Sullivan has evolved into one of the premier growth consulting companies in the world. For more information, visit

Stacie Jones